Kelly M. Thomas

Kelly M. Thomas

Auto-generated profile, based on publicly available information

Kelly M. Thomas

National Infection Service, Public Health England, Salisbury, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SFShuo Feng
Shuo Feng
DPDaniel J. Phillips
Daniel J. Phillips
TWThomas White
Thomas White
HSHomesh Sayal
Homesh Sayal
PAParvinder K. Aley
Parvinder K. Aley
MVMerryn Voysey
Merryn Voysey
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.

23 April 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
KBKevin R Bewley
Kevin R Bewley
NCNaomi Coombes
Naomi Coombes
LGLuc Gagnon
Luc Gagnon
LMLorna McInroy
Lorna McInroy
NBNatalie Baker
Natalie Baker
SCSue Charlton
Sue Charlton

17 December 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JBJordan R. Barrett
Jordan R. Barrett
SBSandra Belij-Rammerstorfer
Sandra Belij-Rammerstorfer
CDChristina Dold
Christina Dold
KEKatie Ewer
Katie Ewer
PFPedro Folegatti
Pedro Folegatti
APAndrew J. Pollard
Andrew J. Pollard

16 March 2023 in EBioMedicine
Verified
Journal Article
Open access
JSJack E. Saunders
Jack E. Saunders
CGCiaran Gilbride
Ciaran Gilbride
SDStuart Dowall
Stuart Dowall
SMSusan Morris
Susan Morris
MUMarta Ulaszewska
Marta Ulaszewska
TLTeresa Lambe
Teresa Lambe
The tick-borne bunyavirus, Crimean-Congo Haemorrhagic Fever virus (CCHFV), can cause severe febrile illness in humans and has a wide geographic range that continues to expand due to tick migration. Currently, there are no licensed vaccines against CCHFV for widespread usage. In this study, we describe the preclinical assessment of a chimpanzee adenoviral vectored vaccine (ChAdOx2 CCHF) which encodes the glycoprotein precursor (GPC) from CCHFV. We demonstrate here that vaccination with ChAdOx2 CCHF induces both a humoral and cellular immune response in mice and 100% protection in a lethal CCHF challenge model. Delivery of the adenoviral vaccine in a heterologous vaccine regimen with a Modified Vaccinia Ankara vaccine (MVA CCHF) induces the highest levels of CCHFV-specific cell-mediated and antibody responses in mice. Histopathological examination and viral load analysis of the tissues of ChAdOx2 CCHF immunised mice reveals an absence of both microscopic changes and viral antigen associated with CCHF infection, further demonstrating protection against disease. There is the continued need for an effective vaccine against CCHFV to protect humans from lethal haemorrhagic disease. Our findings support further development of the ChAd platform expressing the CCHFV GPC to seek an effective vaccine against CCHFV. This research was supported by funding from the Biotechnology and Biological Sciences Research Council (UKRI-BBSRC) [BB/R019991/1 and BB/T008784/1].

10 September 2021 in Science Advances
Verified
Journal Article
Open access
KBKevin R Bewley
Kevin R Bewley
KGKaren Gooch
Karen Gooch
KTKelly M. Thomas
Kelly M. Thomas
SLStephanie Longet
Stephanie Longet
NWNathan Wiblin
Nathan Wiblin
MCMiles W. Carroll
Miles W. Carroll
No evidence of vaccine-enhanced disease was observed following inactivated SARS-CoV-2 vaccine in ferrets or rhesus macaques.

26 July 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
TLTeresa Lambe
Teresa Lambe
ASAlexandra J. Spencer
Alexandra J. Spencer
KTKelly M. Thomas
Kelly M. Thomas
KGKaren E. Gooch
Karen E. Gooch
STStephen Thomas
Stephen Thomas
SGSarah Gilbert
Sarah Gilbert
Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titre were boosted by a second dose. Data from these challenge models on the absence of enhanced disease and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.